A b s t r a c t
Following isotonic lysis, nucleated cells were stained with fluorochrome-conjugated antibodies to the following antigens: CD3, CD5, CD10, CD11c, CD14, CD16, CD19, CD20, CD22, CD23, CD38, CD45, and κ and λ immunoglobulin light chains. All antibody conjugates were obtained from Becton Dickinson Biosciences, San Jose, CA. Analysis was performed on a FACSCalibur instrument (Becton Dickinson), and the data were processed using CellQuest software (Becton Dickinson). Immunoperoxidase stains were performed on the B-5-fixed, decalcified, paraffin-embedded bone marrow biopsy specimen using previously described techniques. 12 The antibodies to CD3 (polyclonal), CD20 (L26), bcl-2 (124), bcl-6 (PB-B6p), and cyclin D1 (DCS-6) were obtained from DAKO, Carpinteria, CA. The antibodies to CD5 (4C7) and CD10 (56C6) were from Novocastra, Burlingame, CA.
Fluorescence in situ hybridization (FISH) studies for CCND1-IgH gene fusion were performed on the peripheral blood specimen using different colored, directly labeled, gene-specific probes (Vysis, Downers Grove, IL) according to previously described methods. 4 
Case Report
A 64-year-old woman with a 29-month history of "chronic lymphocytic leukemia" sought care because of new-onset fatigue and lassitude. The previous diagnosis of chronic lymphocytic leukemia was based on persistent peripheral blood lymphocytosis; immunophenotyping studies reportedly were not performed. The physical examination revealed marked splenomegaly without appreciable lymphadenopathy. Peripheral blood CBC analysis showed a marked leukocytosis (WBC count, 378,000/µL [378.0 × 10 9 /L]) associated with anemia (hemoglobin, 7.7 g/dL [77 g/L]) and thrombocytopenia (platelet count, 72 × 10 3 /µL [72 × 10 9 /L]). An initial manual differential count was performed, and 80% (0.80) of the WBCs were thought to represent lymphocytes and 10% "blasts." Based on these findings, the possibility of acute leukemia was raised, and peripheral blood and bone marrow biopsy specimens were submitted for analysis.
On review of the peripheral blood smear, 2 morphologically distinct groups of lymphocytes were identified. One was composed of cells having small nuclei with condensed chromatin and irregular nuclear contours and the other of cells having larger nuclei with delicately reticulated chromatin, multiple nucleoli, and densely basophilic, vacuolated cytoplasm ❚Image 1❚. These cell populations were present in relatively equivalent proportions.
Flow cytometric analysis revealed the peripheral blood leukocytes to be largely composed of CD19+ B cells with bright, monoclonal, κ sIg light chain expression ❚Image 2A❚. However, despite the relatively uniform staining intensity for CD19 and κ light chain, it was evident that 2 immunophenotypically distinct monoclonal B-cell populations were present. One cell population, located primarily in the small lymphocyte gate (forward scatter and side scatter gating), stained brightly with antibodies to CD20 and CD45 and expressed CD5; these cells did not coexpress CD10 or CD23 and showed partial, dim staining with antibodies to CD38 ❚Image 2B❚. The second cell population, found in the large lymphocyte gate, expressed CD10 and CD38 and was CD5-and CD23-❚Image 2C❚. In comparison with the CD5+ cells, this second cell population showed slightly diminished staining intensity for CD45.
A diagnosis of MCL was considered based on the presence of clonal, CD5+ B cells; however, it was unclear whether the CD10+CD5-B-cell clone was a related or second, distinct process. FISH studies performed on the peripheral blood specimen demonstrated CCND1-IgH gene fusion in 93% of 500 analyzed nuclei, confirming a diagnosis of MCL. The percentage of FISH-positive cells was approximately equal to the percentage of peripheral blood lymphocytes by manual differential (95% [0.95]), indicating that CCND1-IgH fusion was present in both the CD5+ and CD10+ lymphocyte subsets.
The bone marrow biopsy specimen was infiltrated densely by neoplastic lymphocytes having blastoid cytologic features with intermediate-sized nuclei, speckled chromatin, multiple small nucleoli, and numerous mitotic figures ❚Image 3A❚. Immunoperoxidase stains demonstrated the neoplastic cells to be CD20+ B cells ❚Image 3B❚ that coexpressed CD10 ❚Image 3C❚ and lacked expression of CD5 ❚Image 3D❚, bcl-2, bcl-6, and the blast-associated antigen CD34 (data not shown). These cells showed uniform nuclear positivity with antibodies to cyclin D1 ❚Image 3E❚, confirming a diagnosis of a BV-MCL with an unusual immunophenotype.
Peripheral blood and bone marrow specimens submitted 6 weeks after diagnosis and the initiation of treatment revealed neither morphologic nor immunophenotypic evidence of residual disease. However, a cerebrospinal fluid specimen submitted 5 months after diagnosis was involved by recurrent CD5-CD10+ BV-MCL.
Discussion
The generally accepted CD5+CD23-MCL-associated immunophenotype frequently is used as a tool to identify potential MCL cases and, thereby, permit the selective use of confirmatory molecular genetic and immunohistochemical studies. 1, 13 The reliance on immunophenotypic screening for MCL is greatest in fluidic specimens (peripheral blood and bone marrow aspirate) and small needle biopsy specimens in which the morphologic clues to the diagnosis might be lacking. Whereas this approach permits the more judicious use of ancillary laboratory studies, the underlying rationale has been challenged by descriptions of varying patterns of antigen expression in MCL. A number of reports have documented MCL cases that lack CD5 expression when assessed by immunoperoxidase or flow cytometric methods. 10, 14, 15 MCL cases with coexpression of CD5 and CD10 also have been reported, although this seems to occur infrequently. 16, 17 None of these immunophenotypic subgroups have been associated specifically with BV-MCL. The potential immunophenotypic heterogeneity of MCL is highlighted further by this case, which represents an extreme example having a blastoid component showing both loss of CD5 and aberrant expression of CD10. Indeed, if a component of the disease had not retained immunophenotypic features typical of MCL, it is improbable that this diagnosis would have been considered.
The advent of complex multicolor flow cytometric instruments with the ability to analyze numerous fluorescence channels has enhanced our ability to assess antigen expression by neoplastic cell populations. This, in turn, has led to increased efforts to identify disease-defining immunophenotypic characteristics in hematolymphoid malignant neoplasms. The case described herein illustrates the potential pitfalls in attempting to subclassify B-cell neoplasms based exclusively on patterns of surface antigen expression. These patterns have been useful in generally categorizing different types of B-cell lymphoproliferative disorders and in helping to identify the physiologic counterparts from which these disorders likely arise. 14, 15, 18 However, although there is ever-expanding knowledge of the diseasespecific genetic abnormalities associated with these disorders, no direct link between these abnormalities and the cellsurface expression of antigens such as CD5 has been elucidated. In contrast, our understanding of these genetic abnormalities has permitted the identification of cases that challenge accepted paradigms of antigen expression in Bcell lymphomas. 
